🚀 VC round data is live in beta, check it out!
Q-linea Valuation Multiples
Discover revenue and EBITDA valuation multiples for Q-linea and similar public comparables like Baumer, Biohit, Sequana Medical, RenovoRx and more.
Q-linea Overview
About Q-linea
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
Founded
2007
HQ
Employees
94
Website
Sectors
Financials (FY)
EV
$17M
Q-linea Financials
Q-linea reported last fiscal year revenue of $1M and negative EBITDA of ($18M).
In the same fiscal year, Q-linea generated ($185K) in gross profit, ($18M) in EBITDA losses, and had net loss of ($20M).
Revenue (LTM)
Q-linea P&L
In the most recent fiscal year, Q-linea reported revenue of $1M and EBITDA of ($18M).
Q-linea expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $1M | XXX | XXX | XXX |
| Gross Profit | — | XXX | ($185K) | XXX | XXX | XXX |
| Gross Margin | — | XXX | (15%) | XXX | XXX | XXX |
| EBITDA | — | XXX | ($18M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1447%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (1630%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($20M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (1644%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Q-linea Stock Performance
Q-linea has current market cap of $44M, and enterprise value of $17M.
Market Cap Evolution
Q-linea's stock price is $2.35.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $17M | $44M | 0.3% | XXX | XXX | XXX | $-1.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialQ-linea Valuation Multiples
Q-linea trades at 14.0x EV/Revenue multiple, and (1.0x) EV/EBITDA.
EV / Revenue (LTM)
Q-linea Financial Valuation Multiples
As of April 20, 2026, Q-linea has market cap of $44M and EV of $17M.
Equity research analysts estimate Q-linea's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Q-linea has a P/E ratio of (2.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $44M | XXX | $44M | XXX | XXX | XXX |
| EV (current) | $17M | XXX | $17M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 14.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.0x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (0.9x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (91.6x) | XXX | XXX | XXX |
| P/E | — | XXX | (2.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Q-linea Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Q-linea Margins & Growth Rates
Q-linea's revenue in the last fiscal year grew by 370%.
Q-linea's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.
Q-linea Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 370% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1447%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (19%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1614% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Q-linea Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Q-linea | XXX | XXX | XXX | XXX | XXX | XXX |
| Baumer | XXX | XXX | XXX | XXX | XXX | XXX |
| Biohit | XXX | XXX | XXX | XXX | XXX | XXX |
| Sequana Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| RenovoRx | XXX | XXX | XXX | XXX | XXX | XXX |
| SciBase Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Q-linea M&A Activity
Q-linea acquired XXX companies to date.
Last acquisition by Q-linea was on XXXXXXXX, XXXXX. Q-linea acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Q-linea
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialQ-linea Investment Activity
Q-linea invested in XXX companies to date.
Q-linea made its latest investment on XXXXXXXX, XXXXX. Q-linea invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Q-linea
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Q-linea
| When was Q-linea founded? | Q-linea was founded in 2007. |
| Where is Q-linea headquartered? | Q-linea is headquartered in Sweden. |
| How many employees does Q-linea have? | As of today, Q-linea has over 94 employees. |
| Who is the CEO of Q-linea? | Q-linea's CEO is Stuart Gander. |
| Is Q-linea publicly listed? | Yes, Q-linea is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Q-linea? | Q-linea trades under QLINEA ticker. |
| When did Q-linea go public? | Q-linea went public in 2018. |
| Who are competitors of Q-linea? | Q-linea main competitors are Baumer, Biohit, Sequana Medical, RenovoRx. |
| What is the current market cap of Q-linea? | Q-linea's current market cap is $44M. |
| What is the current revenue of Q-linea? | Q-linea's last fiscal year revenue is $1M. |
| What is the current EV/Revenue multiple of Q-linea? | Current revenue multiple of Q-linea is 14.0x. |
| Is Q-linea profitable? | No, Q-linea is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.